News | Artificial Intelligence | November 01, 2023

The solution helps to prioritize worklists and expedite diagnosis for patients with urgent conditions 

The solution helps to prioritize worklists and expedite diagnosis for patients with urgent conditions

November 1, 2023 — Annalise.ai, a global leader in the radiology imaging sector, announced the launch of Annalise Triage, a solution tailored specifically for the U.S. market. This innovative software will transform the radiology field by empowering radiologists to efficiently triage studies and prioritize those with suspected critical findings, ultimately streamlining their workflow, and supporting faster time-to-diagnosis for urgent conditions. AI-enhanced worklist triaging has been shown to decrease both the time a radiologist needs to read a report, and the time from request until a report is available for critical cases.1  

Annalise Triage boasts an impressive array of 12 FDA-cleared findings, including 5 for chest X-ray (CXR) and 7 for non-contrast head CT (CTB). Readily available for use across the United States, this comprehensive offering received the 510(k) clearance and the coveted breakthrough designation for obstructive hydrocephalus. Notably, Annalise Triage is the only radiology triage device to have received this distinction, which is exclusively granted to devices and products that fulfil specific criteria, which include enhancing the diagnosis or treatment of life-threatening or irreversibly debilitating conditions, offering breakthrough technology, presenting a significant advantage over existing alternatives, and being in the best interest of patients.2  

By implementing Annalise Triage, radiologists can swiftly and accurately detect a range of critical, time-sensitive conditions from unenhanced head CT studies, including acute subdural hematoma, acute subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, obstructive hydrocephalus, mass effect, and vasogenic edema. Furthermore, it enables identification of pleural effusion, pneumoperitoneum, vertebral compression fracture, pneumothorax, and tension pneumothorax on chest X-rays. With this list of 12 time-sensitive and critical findings, Annalise Triage is the most comprehensive AI triage tool for CXR and non-contrast CTB available in the US.  

In light of growing imaging backlogs and radiology workforce shortages, Annalise Triage is strategically positioned to address the pressing need to improve workflow efficiency in U.S. radiology. Worklist prioritization has emerged as a crucial use case for AI in radiology, and Annalise.ai is at the forefront of this transformative trend. Annalise.ai recognized the current industry challenges and expedited regulatory approvals to be one of the fastest AI providers to achieve 12 findings cleared by FDA in under 2 years.  

Dr Rick Abramson, Chief Medical Officer at Annalise.ai, added: “Our advanced algorithms support radiologists by facilitating prioritization of studies with suspected critical findings, thereby optimizing radiology workflow. With its set of clearances, Annalise.ai promotes faster report turnaround times by identifying and elevating critical cases for immediate attention.”    

One of Annalise's key strengths in the U.S. radiology triage market is the breadth and depth of its triage findings. Annalise Triage offers the most extensive radiology triage portfolio available in the United States for chest X-ray and un-enhanced head CT, aligning seamlessly with the company's track record of providing one of the most comprehensive diagnostic support portfolios worldwide. Annalise.ai algorithms are powered by one of the world’s largest, most diverse datasets and trained using a pool of 140+ fully qualified consulting radiologists.  

Annalise.ai's commitment to innovation and its dedication to improving patient care continue to drive advancements in radiology. Annalise Triage is poised to redefine the radiology triage landscape in the United States, empowering healthcare professionals with cutting-edge technology with worklist prioritization to improve patient outcomes.  

For more information: https://annalise.ai/ 

Find more RSNA conference coverage here 

 

References: 

Karunasena S et al., 2022  

Breakthrough Devices Program | FDA  


Related Content

News | Ultrasound Imaging

July 7, 2026 — Longeviti Neuro Solutions has launched a new strategic initiative, ClearFit AI, a Brain Ultrasound ...

Time July 09, 2026
arrow
News | Prostate Cancer

July 8,2026 — CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, has announced the ...

Time July 08, 2026
arrow
News | Women's Health

July 1, 2026 — Despite declining birth rates worldwide, the complexity of pregnancy is increasing. Advanced maternal age ...

Time July 01, 2026
arrow
News | Information Technology

June 26, 2026 — Radin Health recently announced the successful deployment of its cloud-native platform at four ...

Time June 26, 2026
arrow
News | FDA

June 25, 2026 — Aidoc recently announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...

Time June 25, 2026
arrow
News | Mammography

June 23, 2026 — Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer ...

Time June 24, 2026
arrow
News | Pediatric Imaging

June 16, 2026 — Crescom has officially launched a global clinical Proof of Concept (PoC) of its pediatric ...

Time June 24, 2026
arrow
News | Information Technology

June 24, 2026 — HOPPR Presto Agent (Presto) is now commercially available from HOPPR. Presto iis a tool that ntegrates ...

Time June 24, 2026
arrow
Feature | X-Ray | Kyle Hardner

Water-window X-rays allow researchers to visualize biological cells at high contrast without staining agents or other ...

Time June 23, 2026
arrow
News | Digital Pathology

June 17, 2026 — Proscia has introduced the Fifth Generation of its Concentriq1 platform, helping pathologists focus on ...

Time June 22, 2026
arrow
Subscribe Now